My Elbow Hurts. Should I Take BPC-157?

A few weeks ago, my elbow started hurting after what was probably too much pulling volume in a hard workout. Nothing dramatic happened. No pop. No obvious tear. Just nagging pain that made certain movements harder to ignore.

I did the usual things. I backed off the movements that aggravated it, rested it and started rehab. It improved, but it has not completely gone away. Tendon problems also become more common as we age, which matters if the goal is to keep training hard for decades. [1]

Then I kept running into the same name: BPC-157.

BPC-157 is an experimental peptide that has become a fixture in recovery conversations. Athletes and biohackers report surprisingly fast improvements in tendon, muscle and joint problems. On Huberman Lab, physician Abud Bakri described the gap plainly: the animal work is intriguing, while the human evidence and sourcing remain major limitations. Andrew Huberman has also described faster recovery in his own experience while explicitly acknowledging that an anecdote cannot establish causation. [2,3]

Then you look at the animal experiments, and the hype becomes easier to understand. In rats with major Achilles tendon and ligament injuries, BPC-157 repeatedly improved healing-related outcomes. Some experiments started treatment only 30 minutes after injury. [4-6]

Then you look for good human trials.

There basically are not any.

Yet BPC-157 is not hard to find online in the United States. It is not FDA-approved, and product quality is a separate problem from whether the molecule itself works. In July 2026, an FDA advisory committee voted 8 to 6, with one abstention, to recommend adding BPC-157-related substances to the 503A compounding list. That was an advisory compounding vote, not FDA approval and not a finding that BPC-157 heals tendons. [7,8]

So this is no longer an abstract biohacking question for me. Should I use it for my elbow?

A 2025 systematic review found 36 musculoskeletal studies on BPC-157. Thirty-five were preclinical and only one was clinical. Across animal models, researchers reported improvements in tendon, ligament, muscle and bone healing. [9]

The early-treatment point matters. The evidence does not support a rule that BPC-157 should only become interesting after an injury has been chronic for months. Several positive animal studies started treatment during the initial repair phase. If those effects translate to humans, early treatment could plausibly be useful.

But that last sentence is the key caveat: if the effects translate to humans. We do not know that they do.

There is another reason to lower confidence. Much of the positive BPC-157 literature comes from a concentrated research group rather than many independent teams repeatedly reproducing the same findings. Peter Attia highlighted this problem in a recent review. Consistency inside one research ecosystem is less convincing than broad independent replication. [10]

The most cited musculoskeletal human report is a small retrospective knee-pain series. Twelve patients received BPC-157 alone and 11 reported significant improvement. There was no placebo group, no randomization and no validated functional outcome that can tell us how much of the improvement came from BPC-157. [11]

Other published human work is similarly small and uncontrolled. A 2025 intravenous safety pilot involved only two people. A 2026 translational review concluded that the available clinical literature remains far too limited to establish an effective dose, efficacy or long-term safety. [12,13]

So saying there are no human data is too strong. Saying BPC-157 has been shown to heal human tendons is much further from the truth.

This is where I do not think the usual evidence hierarchy tells the whole story.

Anecdotes are weak evidence for causation. Injuries naturally improve. People rest, change their training, start rehab and try several things at once. They also tend to start an experimental treatment when symptoms are at their worst, which makes improvement afterward easy to attribute to the newest intervention.

But repeated human reports are not meaningless either. Recent biohacking discussions include people using BPC-157 specifically for stubborn tennis elbow and other tendon problems, with reports ranging from dramatic improvement to no clear effect to adverse reactions. Even family physicians are now reporting that patients routinely tell them they are taking unapproved peptides, including BPC-157. [14-16]

That is a signal worth studying. It is not enough to tell us the success rate, the effect size, the best timing or the best dose.

BPC-157's safety story is mostly uncertainty, not proof of major harm. FDA says the available human safety information is limited and raises concerns about immunogenicity, peptide-related impurities and exactly which BPC-157-related active ingredient is being compounded. [17]

That creates two separate questions. Does BPC-157 work? And if it does, can you trust what is actually in the product you are getting?

Regulation also depends on where you live. Canada, for example, treats injectable peptides as prescription drugs and has warned consumers not to use unauthorized BPC-157 products sold online. Health Canada obtained a permanent injunction this year against a seller of unauthorized injectable peptides. Check the current rules in your own country rather than assuming U.S. access applies everywhere. [18,19]

Competitive athletes have another issue: BPC-157 is prohibited at all times under WADA's non-approved-substances category. [20]

There is no evidence-based number of days, weeks or pain score where BPC-157 suddenly becomes a good idea. The useful way to think about it is risk versus potential reward.

Healthy, no injury: no. I found no convincing evidence that preventive BPC-157 reduces future injuries or improves healthspan. There is no meaningful problem to solve.

Minor overuse ache: probably no. The chance of ordinary recovery is high, so the potential added benefit is small relative to the uncertainty.

Meaningful new tendon, muscle or ligament injury: maybe. This is more interesting than I expected because the animal signal is largely a healing signal, and early repair may be a relevant window. That is biological plausibility, not a human treatment recommendation.

Persistent or recurrent injury despite appropriate rehab: stronger maybe. Not because BPC-157 has been shown to work better late, but because the cost of continuing to struggle with the injury is higher. Accepting uncertainty becomes more rational as the problem becomes more consequential.

Major acute injury, major weakness or a suspected tear: diagnose it first. An experimental peptide should never delay finding out whether you have a rupture, fracture or another problem with established treatment.

BPC-157 is too promising to dismiss as Noise, but the human evidence is far too weak to treat it like an established therapy. The animal healing signal is unusually consistent. The real-world human signal is interesting. The controlled human efficacy evidence is almost absent.

For a healthy person looking for better recovery, the minimum effective dose is zero.

For a meaningful injury, especially one that threatens training or keeps recurring despite appropriate rehab, BPC-157 becomes a legitimate experimental option to discuss with a qualified clinician. A new injury may also be a biologically plausible window, but we do not yet have human trials showing that starting early improves recovery.

Start with the basics that already work: determine whether the injury needs a diagnosis, modify the load that is aggravating it and use progressive rehab. Do not use BPC-157 to numb the decision and keep repeating the training error that caused the problem.

If the injury is meaningful enough that BPC-157 still looks attractive after you understand the evidence gap, product quality, medical oversight and local regulation become part of the decision.

For my elbow, BPC-157 has moved from something I would have dismissed as internet peptide hype to something I would consider if the problem remains limiting despite rehab. That is not the same as saying I should take it today.

The better question is not simply, “Does BPC-157 work?” It is, “Is this injury important enough that the potential upside is worth the uncertainty?”

Related: [Edition #006] Resistance Training.

Subscribe free — one edition in your inbox every Wednesday. No spam. No conflicts of interest. Any future sponsorships will be clearly disclosed and personally vetted.

After subscribing, check your junk/spam folder for the confirmation email and mark it as ‘Not Spam’ to ensure delivery.